Free Trial

Galectin Therapeutics (GALT) Competitors

Galectin Therapeutics logo
$5.30 +0.21 (+4.13%)
Closing price 10/21/2025 04:00 PM Eastern
Extended Trading
$5.17 -0.13 (-2.45%)
As of 10/21/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GALT vs. ELVN, TRVI, WVE, ORIC, SNDX, TRML, NBTX, MAZE, ARDX, and CVAC

Should you be buying Galectin Therapeutics stock or one of its competitors? The main competitors of Galectin Therapeutics include Enliven Therapeutics (ELVN), Trevi Therapeutics (TRVI), WAVE Life Sciences (WVE), Oric Pharmaceuticals (ORIC), Syndax Pharmaceuticals (SNDX), Tourmaline Bio (TRML), Nanobiotix (NBTX), Maze Therapeutics (MAZE), Ardelyx (ARDX), and CureVac (CVAC). These companies are all part of the "pharmaceutical products" industry.

Galectin Therapeutics vs. Its Competitors

Galectin Therapeutics (NASDAQ:GALT) and Enliven Therapeutics (NASDAQ:ELVN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

In the previous week, Enliven Therapeutics had 2 more articles in the media than Galectin Therapeutics. MarketBeat recorded 5 mentions for Enliven Therapeutics and 3 mentions for Galectin Therapeutics. Galectin Therapeutics' average media sentiment score of 0.56 beat Enliven Therapeutics' score of 0.16 indicating that Galectin Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Galectin Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Enliven Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Galectin Therapeutics has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Comparatively, Enliven Therapeutics has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500.

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Galectin Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Galectin TherapeuticsN/AN/A-$47.05M-$0.64-8.28
Enliven TherapeuticsN/AN/A-$89.02M-$2.00-10.60

Galectin Therapeutics' return on equity of 0.00% beat Enliven Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Galectin TherapeuticsN/A N/A -225.32%
Enliven Therapeutics N/A -29.15%-27.88%

Galectin Therapeutics presently has a consensus target price of $6.00, indicating a potential upside of 13.21%. Enliven Therapeutics has a consensus target price of $41.20, indicating a potential upside of 94.43%. Given Enliven Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Enliven Therapeutics is more favorable than Galectin Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Galectin Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Enliven Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67

11.7% of Galectin Therapeutics shares are held by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are held by institutional investors. 50.1% of Galectin Therapeutics shares are held by company insiders. Comparatively, 25.9% of Enliven Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Galectin Therapeutics and Enliven Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

Get Galectin Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GALT vs. The Competition

MetricGalectin TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$326.07M$3.01B$6.22B$10.68B
Dividend YieldN/A57.76%5.72%4.88%
P/E Ratio-8.2823.5929.1427.22
Price / SalesN/A759.39582.41131.48
Price / CashN/A171.3937.5161.65
Price / Book-3.155.4112.476.59
Net Income-$47.05M$33.06M$3.32B$276.14M
7 Day Performance2.12%-0.68%0.79%-0.72%
1 Month Performance7.72%8.13%7.32%2.47%
1 Year Performance102.29%-2.15%63.84%33.90%

Galectin Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GALT
Galectin Therapeutics
1.075 of 5 stars
$5.30
+4.1%
$6.00
+13.2%
+101.5%$326.07MN/A-8.289
ELVN
Enliven Therapeutics
2.0934 of 5 stars
$22.12
+3.3%
$41.20
+86.3%
-26.6%$1.27BN/A-11.0650Insider Trade
TRVI
Trevi Therapeutics
2.6767 of 5 stars
$10.69
+3.2%
$21.75
+103.5%
+217.9%$1.26BN/A-25.4520Gap Down
WVE
WAVE Life Sciences
4.7402 of 5 stars
$7.81
flat
$20.57
+163.4%
-48.0%$1.24B$108.30M-8.68240Analyst Forecast
ORIC
Oric Pharmaceuticals
4.3555 of 5 stars
$12.38
-3.1%
$17.29
+39.6%
+38.2%$1.24BN/A-6.5580Positive News
SNDX
Syndax Pharmaceuticals
4.0769 of 5 stars
$15.57
+8.9%
$38.00
+144.1%
-22.2%$1.23B$23.68M-4.00110Positive News
Analyst Revision
High Trading Volume
TRML
Tourmaline Bio
1.6025 of 5 stars
$47.93
+0.1%
$45.65
-4.8%
+69.3%$1.23BN/A-13.9744Positive News
Short Interest ↓
High Trading Volume
NBTX
Nanobiotix
0.8504 of 5 stars
$24.52
-4.2%
$11.00
-55.1%
+370.3%$1.23B$39.18M0.00100Gap Down
MAZE
Maze Therapeutics
2.5916 of 5 stars
$29.75
+7.0%
$33.83
+13.7%
N/A$1.22B$167.50M0.00121Short Interest ↑
ARDX
Ardelyx
4.2919 of 5 stars
$5.10
+1.4%
$11.70
+129.4%
-10.0%$1.21B$333.61M-22.1790
CVAC
CureVac
3.5145 of 5 stars
$5.36
flat
$6.83
+27.5%
+93.9%$1.20B$579.18M5.58880

Related Companies and Tools


This page (NASDAQ:GALT) was last updated on 10/22/2025 by MarketBeat.com Staff
From Our Partners